<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Indications, dosing, and adverse effects of biologic agents used for severe asthma&lt;sup&gt;*&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Indications, dosing, and adverse effects of biologic agents used for severe asthma<sup>*</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Indications, dosing, and adverse effects of biologic agents used for severe asthma<sup>*</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="12%"></colgroup><colgroup width="28%"></colgroup> <tbody> <tr> <td class="subtitle1">Agent and target</td> <td class="subtitle1">US FDA-approved age</td> <td class="subtitle1">Approved indication<sup>¶</sup></td> <td class="subtitle1">Route</td> <td class="subtitle1">Dose</td> <td class="subtitle1">Dosing interval</td> <td class="subtitle1">Adverse effects</td> </tr> <tr> <td>Omalizumab (anti-IgE)</td> <td>≥6 years</td> <td>IgE 30 to 700 int. units/mL in United States; 30 to 1500 int. units/mL in Europe</td> <td>SC<sup>Δ</sup></td> <td> <p>Based on weight and IgE</p> <p>Doses ≥225 mg need to be divided over &gt;1 injection site</p> Maximal dose: 375 mg every 2 weeks in United States; 600 mg every 2 weeks in Europe</td> <td>2 to 4 weeks depending on IgE level and body weight</td> <td> <ul> <li>Local injection site reaction (severe 12%), usually within 1 hour</li> <li>Thromboembolic disease ≤3%</li> <li>Anaphylaxis, immediate or delayed &lt;1%</li> <li>Antibody development (&lt;1%)</li> </ul> </td> </tr> <tr> <td>Mepolizumab (anti-IL-5)</td> <td>≥6 years</td> <td>Peripheral blood eosinophils ≥150/microL</td> <td>SC<sup>Δ</sup></td> <td> <p>Adults and adolescents: 100 mg</p> Children age 6 to 11 years: 40 mg</td> <td>4 weeks</td> <td> <ul> <li>Headache (19%)</li> <li>Local injection site reaction (8 to 15%)</li> <li>Anaphylaxis: Immediate or delayed &lt;1%</li> <li>Human anti-human neutralizing antibody (&lt;1%)</li> <li>Herpes zoster (&lt;1%): Administration of zoster vaccine is suggested prior to initiation</li> </ul> </td> </tr> <tr> <td>Benralizumab (anti-IL-5 receptor alpha)</td> <td>≥12 years</td> <td>Peripheral blood eosinophils ≥150/microL</td> <td>SC</td> <td>30 mg</td> <td>4 weeks for first 3 doses, then 8 weeks</td> <td> <ul> <li>Human anti-human antibody development (13%; neutralizing 12%)</li> <li>Headache 8%</li> <li>Fever 3%</li> <li>Hypersensitivity (anaphylaxis, angioedema, urticaria; 3%): typically within hours of injection but can be delayed (3%)</li> </ul> </td> </tr> <tr> <td rowspan="2">Dupilumab (anti-IL-4 receptor subunit <span class="nowrap_whitespace">alpha)<sup>§</sup></span></td> <td rowspan="2">≥6 years</td> <td rowspan="2">Peripheral blood eosinophils ≥150/microL</td> <td rowspan="2">SC<sup>Δ</sup></td> <td> <p>Adults and adolescents: First week, 400 mg once (given as two 200 mg injections), then 200 mg</p> <p>Children age 6 to 11 years:</p> <p class="indent1">100 mg<sup>◊</sup>, for children 15 to &lt;30 kg;</p> <p class="indent1 extra_spacing_top">200 mg, for children ≥30 kg</p> </td> <td>2 weeks</td> <td rowspan="2"> <ul> <li>Human anti-human antibody development in patients receiving the 300 mg dose every 2 weeks for 52 weeks (6%; 2% neutralizing antibodies) and in patients taking 200 mg dose every 2 weeks for 52 weeks (9%; 4% neutralizing antibodies)</li> <li>Transient eosinophilia (4%); over 3000 cells/mL (1.2%)</li> <li>Anaphylaxis and other hypersensitivity reactions (&lt;1%)</li> <li>Injection site reactions, conjunctivitis, keratitis, oral and other herpes simplex viral infections</li> </ul> </td> </tr> <tr> <td>First week, 600 mg once (given as two 300 mg injections), then 300 mg<span class="nowrap_whitespace"><sup>§</sup></span></td> <td>2 weeks</td> </tr> <tr> <td>Reslizumab (anti-IL-5)</td> <td>≥18 years</td> <td>Peripheral blood eosinophils ≥400/microL</td> <td>IV</td> <td>3 mg/kg</td> <td>4 weeks</td> <td> <ul> <li>Human anti-human antibody development (5%)</li> <li>Anaphylaxis 0.3% during infusion or within 30 minutes after infusion; may occur as early as second dose or can be delayed</li> <li>Transient increase in creatine phosphokinase (20%)</li> </ul> </td> </tr> <tr> <td>Tezepelumab</td> <td>≥12 years</td> <td>No additional requirements</td> <td>SC<sup>Δ</sup></td> <td>210 mg</td> <td>Every 4 weeks</td> <td> <ul> <li>Antibody development (2%; neutralizing &lt;1%)</li> <li>Anaphylaxis and hypersensitivity reactions typically within hours but can be after days</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">These agents are for use in patients with uncontrolled asthma despite regular use of a combination of medium- to high-dose inhaled glucocorticoid and long-acting beta-2 agonists and <font class="nowrap_whitespace">FEV<sub>1</sub></font> &lt;80% predicted. For patients who meet indications for multiple biologic agents, our approach to selection is based on several factors including assessment of type 2 allergic comorbidities, timing of disease-onset, allergen sensitivity, blood eosinophil level, and fraction of exhaled nitric oxide. Refer to UpToDate topic on management of severe asthma and accompanying algorithm on biologic agent selection for additional details regarding choice of therapy and administration.</div><div class="graphic_footnotes"><p><font class="nowrap_whitespace">FEV<sub>1</sub>:</font> forced expiratory volume in one second; IgE: total serum immunoglobulin E; IL-5: interleukin-5; IV: intravenous infusion; SC: subcutaneous injection; TSLP: thymic stromal lymphopoietin; US FDA: United States Food and Drug Association.</p>
<p>* Helminth infection should be excluded or treated prior to initiation of therapy. These agents should be administered in a setting prepared to handle anaphylaxis. Patients should be observed for two hours after each of the first three injections and for 30 minutes after each subsequent injection. It is advised that patients receiving omalizumab should carry an epinephrine autoinjector for at least 24 hours after each injection due to late occurrences of anaphylaxis.</p>
<p>¶ This column notes indications in addition to the diagnosis of poorly controlled severe asthma despite inhaled therapies, which is required for all biologic agents.</p>
<p>Δ Mepolizumab, dupilumab, and tezepelumab can be administered at home after appropriate training. Omalizumab is available for home administration in some countries, including the United States. Refer to UpToDate content for additional information.</p>
<p>◊ For children age 6 to 11 years 15 to &lt;30 kg with severe asthma, dupilumab may also be dosed 300 mg every <em>four</em> weeks. Alternative dosing regimens are used for moderate to severe atopic dermatitis.</p>
§ The higher dose of dupilumab is advised for adults or adolescents with oral glucocorticoid-dependent asthma or comorbid moderate to severe atopic dermatitis.</div><div class="graphic_reference">References:
<ol>
<li>US Food and Drug Administration. Omalizumab (Xolair). <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf" target="_blank">http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/103976s5225lbl.pdf</a>.</li>
<li>European Medicines Agency. Xolair. <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/xolair" target="_blank">https://www.ema.europa.eu/en/medicines/human/EPAR/xolair</a>.</li>
<li>Cox L, Platts-Mills TAE, Finegold I et al. American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007;120:1373-77.</li>
<li>US Food and Drug Administration. Mepolizumab (Nucala). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125526s012,761122s002s003lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125526s012,761122s002s003lbl.pdf</a>.</li>
<li>US Food and Drug Administration. Reslizumab (Cinqair) prescribing information. <a href="https://www.cinqair.com/globalassets/cinqair/prescribinginformation.pdf" target="_blank">https://www.cinqair.com/globalassets/cinqair/prescribinginformation.pdf</a>.</li>
<li>US Food and Drug Administration. Benralizumab (Fasenra). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761070s000lbl.pdf</a>.</li>
<li>US Food and Drug Administration. Dupilumab (Dupixent). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf</a>.</li>
<li>US Food and Drug Administration. Tezepelumab (Tezspire). <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761224s001lbl.pdf</a>.</li>
</ol></div><div id="graphicVersion">Graphic 118483 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
